A detailed history of Black Rock Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 430,368 shares of SLS stock, worth $525,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares
430,368
Previous 278,218 54.69%
Holding current value
$525,048
Previous $281,000 82.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.06 - $1.63 $161,279 - $248,004
152,150 Added 54.69%
430,368 $512,000
Q1 2024

May 10, 2024

SELL
$0.51 - $1.55 $808 - $2,458
-1,586 Reduced 0.57%
278,218 $281,000
Q4 2023

Feb 13, 2024

SELL
$0.88 - $1.57 $696 - $1,243
-792 Reduced 0.28%
279,804 $296,000
Q3 2023

Nov 13, 2023

SELL
$1.42 - $1.83 $3,936 - $5,072
-2,772 Reduced 0.98%
280,596 $460,000
Q2 2023

Aug 11, 2023

BUY
$1.35 - $1.8 $29,544 - $39,393
21,885 Added 8.37%
283,368 $444,000
Q1 2023

May 12, 2023

BUY
$1.18 - $3.86 $1,862 - $6,091
1,578 Added 0.61%
261,483 $373,000
Q4 2022

Feb 13, 2023

BUY
$1.8 - $5.41 $6,561 - $19,719
3,645 Added 1.42%
259,905 $613,000
Q3 2022

Nov 14, 2022

SELL
$2.02 - $3.38 $2,514 - $4,208
-1,245 Reduced 0.48%
256,260 $517,000
Q2 2022

Aug 12, 2022

BUY
$2.14 - $4.15 $9,873 - $19,148
4,614 Added 1.82%
257,505 $574,000
Q1 2022

May 12, 2022

SELL
$4.73 - $7.18 $9,237 - $14,022
-1,953 Reduced 0.77%
252,891 $1.69 Million
Q4 2021

Feb 10, 2022

BUY
$5.36 - $9.53 $10,752 - $19,117
2,006 Added 0.79%
254,844 $1.41 Million
Q3 2021

Nov 09, 2021

BUY
$8.21 - $10.53 $2,939 - $3,769
358 Added 0.14%
252,838 $2.32 Million
Q2 2021

Aug 11, 2021

BUY
$7.19 - $13.71 $1.82 Million - $3.46 Million
252,480 New
252,480 $2.8 Million

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $25.1M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.